Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Date:4/23/2009

SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the first quarter ended March 31, 2009.

"We have now concluded three Phase I trials of ANA598, including a study in HCV patients that demonstrated potent antiviral activity over three days," said Steve Worland, Ph.D., Anadys' President and CEO. "Coupled with very favorable results at three months in our chronic toxicology studies and ongoing manufacturing activities, the conclusion of these Phase I clinical studies positions the program to be ready in mid-2009 for the first Phase II study of ANA598 in combination with pegylated interferon and ribavirin, a study with the potential to demonstrate the impact of ANA598 on durable clinical benefit, known as SVR, in HCV patients."

Financial Results

As of March 31, 2009, the Company's cash, cash equivalents and securities available-for-sale totaled $20.8 million compared to $27.9 million as of December 31, 2008.

Research and development expenses were $6.9 million for the first quarter of 2009 compared to $6.0 million for the first quarter of 2008. The $0.9 million increase primarily resulted from a $1.7 million increase in development costs for ANA598 in the first quarter of 2009 compared to the first quarter of 2008, partially offset by a decrease in our ANA773 development costs. The ANA598 development costs were associated with our completed Phase Ib clinical trial which was initiated during September 2008, our 14-day healthy volunteer study which was initiated in February 2009 and our on-going long-term chronic toxicology studies which were initiated during Septe
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 Immunology ... leading Immunologists, Principle Investigators, scientists in the field, ... Malemud, Professor at Case Western Reserve University School ... keynote address on “The effects of recombinant ... of matrix metalloproteinase-9”. Arya Biragyn, a Senior investigator ...
(Date:7/29/2014)... “PharmaSphere: Emerging Biotech Investment Report Strategic ... report provides in-depth analysis of the current trends ... capital segments of the financial industry, bearing in ... impact on the future of emerging biotechnology companies ... identifies regions of the world that are attracting ...
(Date:7/29/2014)... 2014   Sequenom, Inc. (NASDAQ: ... genetic analysis solutions, and Mayo Medical Laboratories (MML), ... the United States , have announced ... applications. "We have great appreciation for Mayo ... we welcome the opportunity to partner with the organization,s ...
(Date:7/29/2014)... Tough, ultralight foam of atom-thick sheets can be made ... invented at Rice University. , In microscopic images, ... with floors and walls that reinforce each other. The ... and walls of graphene oxide that self-assemble with the ... researchers say the foam could find use in structural ...
Breaking Biology Technology:Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4Tough foam from tiny sheets 2
... ... Supplies Procurement, CARY, N.C., April ... and research-centric organizations realize,the potential of strategic procurement, today announced ... chosen SciQuest,s eprocurement platform to automate,procurement functions for each of ...
... Premier Research Group plc (AIM:,PRG), the international ... a leader in the electronic transformation of ... announce the formalization of a,partnership agreement to ... new partnership combines Octagon,s expertise in electronic,submissions ...
... is a leader,in vision healthcare -- serving people ... years., According to Dr. Tara A Cortes, ... a dramatic breakthrough in gene therapy that could ... According to Yocasta Urena, 28, an employee ...
Cached Biology Technology:Array BioPharma Selects SciQuest to Automate Procurement and Enable Agile Drug Development 2Premier Research Group plc and Octagon Research Solutions, Inc. Announce Strategic Partnership 2
(Date:7/29/2014)... of cell, including sperm, bacteria and algae, propel ... protrusions, about one-hundredth of a millimetre long, function ... Similar, shorter structures called cilia are found on ... roles such as moving liquids over the cell. ... they transport mucus and expel pathogens from our ...
(Date:7/28/2014)... the U.S. Food and Drug Administration (FDA) for other ... pathogens inside human cells, including those that cause Legionnaires, ... in mBio , the online open-access journal of ... of identifying non-antibiotic drugs that could one day help ... on the list inhibit the growth of at least ...
(Date:7/28/2014)... reached the South Pole in 1911, but new research ... human. , Using data from 16 ice cores collected ... the South Pole, a group led by Joe McConnell ... created the most accurate and precise reconstruction to date ... record, described in an article published today in the ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3New route to identify drugs that can fight bacterial infections 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... Fred Kraus from Bishop Museum, Honolulu has ... makes them the world,s smallest tetrapods (non-fish vertebrates). The frogs belong ... extremely small, with adults of the two new species - named ... 8-9 mm in length. The study was published in the open ...
... could be helped with alternative scanning techniques that provide ... University of Edinburgh used an imaging technique that could ... to replace their heart valves, and improve treatments to ... the heart,s aortic valve a common condition known ...
... Dec. 12, 2011  The Evermedia Group, Inc. (Pinksheets: ... Markets last month, raising the Company,s listing from ... Current Information tier, the highest level of reporting ... Evermedia submitted an Initial Company Information and Disclosure ...
Cached Biology News:World's smallest frogs discovered in New Guinea 2New scanning strategy could help develop heart disease treatments 2The Evermedia Group, Inc. Advances Corporate Transparency Efforts 2The Evermedia Group, Inc. Advances Corporate Transparency Efforts 3
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
...
Polaroid black & white positive, 3 x 4 inch pack film, ISO 3000/ 36 ASA DIN (20 expsures). For use in the Polaroid Direct Copy Camera (PHC34)....
SHEEP ANTI ECHIS OCCELATUS (VENOM)...
Biology Products: